<DOC>
	<DOCNO>NCT00316329</DOCNO>
	<brief_summary>Primary Objective : - To demonstrate non-inferiority , term clinical parasitological efficacy D28 administration Coarsucam™ ( artesunate+amodiaquine fixed-dose combination ) , single daily dose , comparison administration Coartem® ( artemether+lumefantrine ) . Secondary Objectives : To compare 3 treatment group term : - clinical parasitological efficacy D14 D28 global population subpopulation consist child age 5 year patient age 5 year - clinical laboratory safety - time parasite clearance - time clearance fever - change gametocytaemia - impact anaemia</brief_summary>
	<brief_title>ATAQ EASY : Artesunate + Amodiaquine Fixed Dose Combination Treatment Uncomplicated Plasmodium Falciparum Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Inclusion criterion : adult child weigh ≥ 10 kg reside zone cover investigate centre throughout entire followup period capable receive oral treatment axillary temperature ≥ 37.5 degree Celsius inclusion visit history fever within previous 24 hour infection Plasmodium falciparum , parasite density blood range 1000 200,000 asexual form per cubic millimetre inform consent participant parent ( guardian ) child negative urinary pregnancy test woman childbearing age Exclusion criterion : presence least one serious clinical danger sign malaria : prostration , consciousness disorder , recent repeat convulsion , respiratory distress , inability drink , uncontrollable vomiting , macroscopic haemoglobinuria , jaundice , haemorrhagic shock , systolic Blood Pressure &lt; 70 mmHg adult &lt; 50 mmHg child , spontaneous bleeding , inability sit stand serious concomitant disease allergy one investigational medicinal product ( drug substance excipient ) pregnant woman ( report , clinically visible palpable pregnancy , positive urinary pregnancy test ) , breastfeed woman clinically documented heart disease ( bradycardia , extrasystole , exertional dyspnoea , systolic diastolic extrasystole , gallop rhythm… ) history hepatic ( ) haematological impairment treatment amodiaquine intake medication metabolise cytochrome CYP2D6 ( e.g . metoprolol , flecainide , imipramine , amitriptyline , clomipramine ) CYP3A4 ( e.g . erythromycin , ketoconazole , itraconazole , cimetidine , HIV protease inhibitor ) family history congenital QTc prolongation sudden death another clinical condition know prolong QTc interval intake medication know prolong QTc interval , class IA III antiarrythmics , neuroleptic , antidepressant agent , certain antibiotic include drug macrolide class , fluoroquinolones , imidazole triazole , antifungal agent , certain nonsedative antihistamine ( terfenadine , astemizole ) cisapride certain know electrolyte imbalance hypokalaemia hypomagnesaemia patient receive artesunate + amodiaquine artemether + lumefantrine suitable dosage within 30 day prior inclusion The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>